$ARDX
Ardelyx Inc

2014 Form 10-K Financial Statement

#000156459015001336 Filed on March 05, 2015

View on sec.gov

Income Statement

Concept 2014 2013 Q4 2013 Q3
Revenue $31.62M $8.488M $6.593M
YoY Change 9.32%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.290M $870.0K $900.0K
YoY Change 97.03%
% of Gross Profit
Research & Development $25.90M $8.340M $6.580M
YoY Change -7.81%
% of Gross Profit
Depreciation & Amortization $302.0K $80.00K $150.0K
YoY Change -48.99%
% of Gross Profit
Operating Expenses $33.19M $9.206M $7.479M
YoY Change 4.38%
Operating Profit -$1.564M -$886.0K
YoY Change -45.41%
Interest Expense -$1.590M -$3.510M $0.00
YoY Change -54.7%
% of Operating Profit
Other Income/Expense, Net $10.00K -$10.00K -$10.00K
YoY Change -119.23%
Pretax Income -$3.147M -$4.230M -$899.0K
YoY Change -51.0%
Income Tax $67.00K $40.00K $35.00K
% Of Pretax Income
Net Earnings -$3.214M -$4.269M -$934.0K
YoY Change -51.04%
Net Earnings / Revenue -10.16% -50.29% -14.17%
Basic Earnings Per Share -$0.81
Diluted Earnings Per Share -$172.7K -$242.9K -$0.81
COMMON SHARES
Basic Shares Outstanding 1.156M
Diluted Shares Outstanding 1.156M

Balance Sheet

Concept 2014 2013 Q4 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $107.3M $34.40M
YoY Change 211.92%
Cash & Equivalents $107.3M $34.44M $23.53M
Short-Term Investments
Other Short-Term Assets $1.200M $1.000M
YoY Change 20.0%
Inventory
Prepaid Expenses
Receivables $2.600M $6.436M
Other Receivables $0.00 $0.00
Total Short-Term Assets $111.1M $41.84M
YoY Change 165.79%
LONG-TERM ASSETS
Property, Plant & Equipment $2.100M $530.0K
YoY Change 320.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $358.0K
YoY Change -60.0%
Total Long-Term Assets $2.300M $1.068M
YoY Change 109.09%
TOTAL ASSETS
Total Short-Term Assets $111.1M $41.84M
Total Long-Term Assets $2.300M $1.068M
Total Assets $113.4M $42.90M
YoY Change 164.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.100M $2.284M
YoY Change 34.78%
Accrued Expenses $2.400M $1.000M
YoY Change 140.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $21.50M $17.14M
YoY Change 25.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $31.20M $33.10M
YoY Change -5.74%
Total Long-Term Liabilities $31.20M $33.10M
YoY Change -5.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.50M $17.14M
Total Long-Term Liabilities $31.20M $33.10M
Total Liabilities $52.70M $50.23M
YoY Change 4.98%
SHAREHOLDERS EQUITY
Retained Earnings -$68.65M
YoY Change
Common Stock $5.174M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $60.70M -$63.48M
YoY Change
Total Liabilities & Shareholders Equity $113.4M $42.90M
YoY Change 164.34%

Cashflow Statement

Concept 2014 2013 Q4 2013 Q3
OPERATING ACTIVITIES
Net Income -$3.214M -$4.269M -$934.0K
YoY Change -51.04%
Depreciation, Depletion And Amortization $302.0K $80.00K $150.0K
YoY Change -48.99%
Cash From Operating Activities $13.40M $10.91M -$200.0K
YoY Change 640.33%
INVESTING ACTIVITIES
Capital Expenditures $1.856M $0.00 -$20.00K
YoY Change 567.63%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.860M $0.00 -$20.00K
YoY Change 564.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net -$61.24M
YoY Change -3062050.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 61.31M 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities 13.40M 10.91M -200.0K
Cash From Investing Activities -1.860M 0.000 -20.00K
Cash From Financing Activities 61.31M 0.000 0.000
Net Change In Cash 72.85M 10.91M -220.0K
YoY Change 4661.44%
FREE CASH FLOW
Cash From Operating Activities $13.40M $10.91M -$200.0K
Capital Expenditures $1.856M $0.00 -$20.00K
Free Cash Flow $11.54M $10.91M -$180.0K
YoY Change 653.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18598133
CY2014Q2 dei Entity Public Float
EntityPublicFloat
96062968
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
107286000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34435000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
180000
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2584000
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6436000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1209000
CY2014Q4 us-gaap Liabilities
Liabilities
52732000
CY2013Q4 us-gaap Liabilities
Liabilities
50228000
CY2013Q4 ardx Liabilities Related To Early Exercise Of Options
LiabilitiesRelatedToEarlyExerciseOfOptions
163000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
965000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
111079000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
41836000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2131000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
530000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
104000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
358000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
100000
CY2014Q4 us-gaap Assets
Assets
113414000
CY2013Q4 us-gaap Assets
Assets
42904000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3129000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2284000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1648000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
927000
CY2014Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
780000
CY2013Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
100000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
15979000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
13828000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21536000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17139000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
122000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
31074000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
26470000
CY2013Q4 ardx Convertible Preferred Stock Warrant Liability
ConvertiblePreferredStockWarrantLiability
6456000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
56155000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
132547000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
5174000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-71867000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68653000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
60682000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-63479000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
113414000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42904000
CY2014Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2013Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
108829748
CY2014Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2013Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
11517222
CY2014Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2013Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
11517222
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2013 us-gaap Revenues
Revenues
28928000
CY2012 us-gaap Revenues
Revenues
5410000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28093000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10184000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3700000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4031000
CY2012 us-gaap Operating Expenses
OperatingExpenses
14215000
CY2014 us-gaap Licenses Revenue
LicensesRevenue
18394000
CY2014 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
13229000
CY2013 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
20865000
CY2014 us-gaap Revenues
Revenues
31623000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25900000
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130360121
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18589245
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1225481
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18589245
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1225481
CY2013 us-gaap Licenses Revenue
LicensesRevenue
8063000
CY2012 us-gaap Licenses Revenue
LicensesRevenue
3182000
CY2012 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
2228000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7287000
CY2014 us-gaap Operating Expenses
OperatingExpenses
33187000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-1564000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-2865000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-52000
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-30000
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1593000
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3506000
CY2012 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
950000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3147000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6423000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
67000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
141000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-3214000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-6564000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-9785000
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.82
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-11.32
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10248337
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1127948
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
864020
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
-48255000
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
175000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
473000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-57392000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
125000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
352000
CY2014 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
56155000
CY2014 ardx Reclassification Of Warrant Liability To Additional Paid In Capital Upon Completion Of Initial Public Offering
ReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalUponCompletionOfInitialPublicOffering
8049000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
238000
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
61241000
CY2014 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
208000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1484000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
302000
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
592000
CY2012 us-gaap Depreciation And Amortization
DepreciationAndAmortization
675000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
1692000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
352000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
473000
CY2013 us-gaap Operating Expenses
OperatingExpenses
31793000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-8805000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9785000
CY2013 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-38000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3852000
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3364000
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3072000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-96000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
438000
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
790000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
831000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1138000
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-105000
CY2014 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
721000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
6755000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
270000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
72851000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1532000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
22122000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32903000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10781000
CY2012 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
760000
CY2013 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
160000
CY2014 us-gaap Stock Issued1
StockIssued1
208000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
7636000
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
32662000
CY2014 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
122000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
13397000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-128000
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
61241000
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
1811000
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
21980000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1856000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
278000
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
128000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1856000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-278000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
71000
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
290000
CY2014 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2000
CY2013 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2000
CY2012 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
20000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
61310000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-1000
CY2014 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
647000
CY2013 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1009000
CY2012 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
212000
CY2014 ardx Reclassification Of Convertible Preferred Warrant Liability To Additional Paid In Capital
ReclassificationOfConvertiblePreferredWarrantLiabilityToAdditionalPaidInCapital
8049000
CY2014 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
56155000
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, clinical trial accruals, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results may differ from those estimates. </p></div>
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash, cash equivalents, and certificates of deposit. Cash and cash equivalents, as well as certificates of deposit held with financial institutions, may exceed the Federal Deposit Insurance Corporation insurance limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents to the extent of the amounts on its balance sheets. The Company has not experienced any losses on its cash, cash equivalents and certificates of deposit during the years ended December&#160;31, 2014, 2013 and 2012. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable are unsecured and are concentrated with one collaboration partner in the pharmaceutical industry, AstraZeneca AB (&#8220;AstraZeneca&#8221;). Accordingly, the Company may be exposed to credit risk generally associated with pharmaceutical companies or specific to the license and collaboration agreement with AstraZeneca. To date the Company has not experienced any losses related to its receivables. </p></div>
CY2014 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2014 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2007-10-17
CY2014 dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
CY2014 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On June 18, 2014, the Company’s Amended and Restated Certificate of Incorporation became effective resulting in a reverse split of the Company’s common stock and convertible preferred stock at a 1-for-9 ratio (the “Reverse Stock Split”). The par value and the authorized shares of the common stock and convertible preferred stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock, convertible preferred stock, warrants for preferred stock, options for common stock and per share amounts contained in the financial statements have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented.
CY2014Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.11
CY2014Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
61200000
CY2014Q2 us-gaap Expense Related To Distribution Or Servicing And Underwriting Fees
ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
7800000
CY2014Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
305000000
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2014Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2014 ardx Cash And Cash Equivalents Original Maturity Dates
CashAndCashEquivalentsOriginalMaturityDates
90 days or less
CY2013 ardx Fair Value Of Preferred Stock Warrant Liability Probability Of Initial Public Offering Scenario Percentage
FairValueOfPreferredStockWarrantLiabilityProbabilityOfInitialPublicOfferingScenarioPercentage
0.20
CY2013 ardx Fair Value Of Preferred Stock Warrant Liability Probability Of Merger Scenario Percentage
FairValueOfPreferredStockWarrantLiabilityProbabilityOfMergerScenarioPercentage
0.10
CY2013 ardx Fair Value Of Preferred Stock Warrant Liability Probability Of Stay Private Scenario Percentage
FairValueOfPreferredStockWarrantLiabilityProbabilityOfStayPrivateScenarioPercentage
0.70
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5765000
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3862000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3634000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3332000
CY2014Q1 us-gaap Cost Of Services Licenses And Services
CostOfServicesLicensesAndServices
200000
CY2013Q4 ardx Temporary Equity Shares Issued And Outstanding
TemporaryEquitySharesIssuedAndOutstanding
11517222
CY2013Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
59074000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2014Q4 us-gaap Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance
DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
1454549
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
19798
CY2012 ardx Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsAuthorized
114428
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
81233
CY2012 ardx Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Exercised In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExercisedInPeriod
0
CY2012 us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
43848
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
96841
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
99552
CY2013 ardx Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Exercised In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExercisedInPeriod
0
CY2013 us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
6625
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3914
CY2014 ardx Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsAuthorized
1452661
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
188888
CY2014 ardx Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Exercised In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExercisedInPeriod
0
CY2014 us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
4084
CY2014 ardx Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Repurchased
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsRepurchased
3511
CY2014 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
10000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1265282
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1598513
CY2012 ardx Share Based Compensation Arrangement By Share Based Payment Award Options Authorized In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorizedInPeriodGross
0
CY2012 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
342131
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
43848
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1293767
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
223865
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
6625
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1162829
CY2014 ardx Share Based Compensation Arrangement By Share Based Payment Award Options Authorized In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorizedInPeriodGross
0
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
336398
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4084
CY2014 ardx Share Based Compensation Arrangement By Share Based Payment Award Options Repurchased In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchasedInPeriodGross
3511
CY2014 ardx Share Based Compensation Arrangement By Share Based Payment Award Options Issuance Of Common Stock For Services In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfCommonStockForServicesInPeriodGross
0
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1007724
CY2014Q4 ardx Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVest
990889
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
643217
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.57
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.46
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.52
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.52
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.77
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.42
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.56
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.23
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.03
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
24.41
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.71
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.21
CY2014 ardx Share Based Compensation Arrangements By Share Based Payment Award Options Repurchased In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice
0.55
CY2014 ardx Share Based Compensation Arrangements By Share Based Payment Award Options Issuance Of Common Stock For Services In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfCommonStockForServicesInPeriodWeightedAverageExercisePrice
0
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.51
CY2014Q4 ardx Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
5.27
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.21
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
14839000
CY2014Q4 ardx Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestIntrinsicValue
14746000
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11376000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.53
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.68
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.56
CY2014Q4 us-gaap Fair Value Assumptions Exercise Price
FairValueAssumptionsExercisePrice
18.89
CY2014 ardx Employee Stock Purchase Plan Initial Offering Period Commenced Period
EmployeeStockPurchasePlanInitialOfferingPeriodCommencedPeriod
2014-09-01
CY2014 ardx Employee Stock Purchase Plan Initial Offering Period Ending Period
EmployeeStockPurchasePlanInitialOfferingPeriodEndingPeriod
2015-02-27
CY2014Q4 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
0
CY2013Q4 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
286217
CY2014Q4 ardx Liabilities Related To Early Exercise Of Options
LiabilitiesRelatedToEarlyExerciseOfOptions
0
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
800000
CY2014Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3200000
CY2014 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M19D
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y26D
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M23D
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.94
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.98
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.97
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0179
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0135
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0079
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.003
CY2012Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2016-09-30
CY2014 us-gaap Provision For Lease Losses
ProvisionForLeaseLosses
100000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.046
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.014
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.179
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.226
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.386
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.206
CY2013 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.208
CY2012 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.052
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.073
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.044
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.032
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.044
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.021
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.022
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
11262000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13069000
CY2014Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
11099000
CY2013Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
9723000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1260000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1734000
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1201000
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
475000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
24822000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
25001000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
24741000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
25001000
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
81000
CY2014Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
81000
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-300000
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1500000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1411000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1064000
CY2011Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
807000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
405000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
999000
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
347000
CY2012 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
257000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2815000
CY2014Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
2800000
CY2013Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
1400000
CY2012Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
1100000
CY2014Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2013Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2012Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1007724
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13255004
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13385942
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
843000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
868000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
895000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
921000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
653000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
4180000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
600000
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
500000
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2014 ardx Indemnification Agreement Termination Written Notification Period
IndemnificationAgreementTerminationWrittenNotificationPeriod
P90D
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2013Q1 us-gaap Revenues
Revenues
6556000
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.81
CY2014Q1 us-gaap Revenues
Revenues
8550000
CY2014Q2 us-gaap Revenues
Revenues
9137000
CY2014Q3 us-gaap Revenues
Revenues
7598000
CY2014Q4 us-gaap Revenues
Revenues
6338000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
9014000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
6386000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
7517000
CY2014Q4 us-gaap Operating Expenses
OperatingExpenses
10270000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-3071000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
3753000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
74000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-3970000
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.44
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.20
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.44
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.18
CY2013Q2 us-gaap Revenues
Revenues
7291000
CY2013Q3 us-gaap Revenues
Revenues
6593000
CY2013Q4 us-gaap Revenues
Revenues
8488000
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
6966000
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
8142000
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
7479000
CY2013Q4 us-gaap Operating Expenses
OperatingExpenses
9206000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-470000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-891000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-934000
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-4269000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.81
CY2013Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.53

Files In Submission

Name View Source Status
0001564590-15-001336-index-headers.html Edgar Link pending
0001564590-15-001336-index.html Edgar Link pending
0001564590-15-001336.txt Edgar Link pending
0001564590-15-001336-xbrl.zip Edgar Link pending
ardx-10k_20141231.htm Edgar Link pending
ardx-20141231.xml Edgar Link completed
ardx-20141231.xsd Edgar Link pending
ardx-20141231_cal.xml Edgar Link unprocessable
ardx-20141231_def.xml Edgar Link unprocessable
ardx-20141231_lab.xml Edgar Link unprocessable
ardx-20141231_pre.xml Edgar Link unprocessable
ardx-ex1020_20141231411.htm Edgar Link pending
ardx-ex1021_20141231413.htm Edgar Link pending
ardx-ex1022_20141231412.htm Edgar Link pending
ardx-ex1023_20141231652.htm Edgar Link pending
ardx-ex231_20141231409.htm Edgar Link pending
ardx-ex311_20141231415.htm Edgar Link pending
ardx-ex312_20141231416.htm Edgar Link pending
ardx-ex321_20141231410.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g201503051349471062859.jpg Edgar Link pending
g201503051349476962863.jpg Edgar Link pending
g201503051349594372909.jpg Edgar Link pending
g201503051350014212910.jpg Edgar Link pending
g201503051350117652911.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending